Why Is INSMED INC (INSM) Stock Down Today?

INSM stock is down 5.26% at $105.27 in the session, driven by the announcement that CFO Sara Bonstein will step down on October 30 after nearly seven years with the company. The stock opened with a small gap up but quickly declined, reaching a session low of $105.24. The leadership transition comes as the company reaffirms its full-year 2026 financial guidance, including a revenue target of $1.25 billion to $1.4 billion for brinsupri and $450 million to $470 million for AriKaye.

What Happened

Insmed announced that CFO Sara Bonstein will leave the company on October 30. She will remain in the role through the Q3 2026 earnings call on October 29. The company emphasized that the transition will not affect its financial guidance for the year. Alongside the leadership update, Insmed reaffirmed its brinsupri and AriKaye revenue projections. The SEC 8-K filing confirmed the departure of Bonstein and outlined the compensatory arrangements for the transition. The news appears to have unsettled investors, despite the company's reaffirmation of its guidance.

What The Data Shows

The stock opened at $112.63 but fell steadily throughout the session. Volume has been light so far at 0.2 million shares, which is 0.1 times the 3-month daily average. The stock has declined 8.4% over the last eight sessions, from $118.34 to $108.40. Recent insider transactions show seven sales totaling $42.9 million in the last 90 days, with no insider purchases recorded. Congressional trades include one buy and two sells in the same period. The stock is currently trading within its 52-week range of $90.39 to $212.75.

What To Watch

The company is scheduled to report Q3 2026 financial results ahead of the CFO’s transition. Investors will be watching for any further commentary on the leadership change and how it may affect the company’s strategic direction. Coverage breadth and sentiment trends will also be key indicators of market reaction.